Clinical Trials Logo

Clinical Trial Summary

This clinical trial studies the use of surveys, blood testing, and fibroscan in screening for liver fibrosis and liver cirrhosis in new or existing patients of the HOPE clinic seeking usual clinical care. Fibroscan is an imaging procedure of the liver which uses a probe like an ultrasound. Information gathered from this study may help researchers learn more about how to prevent or find liver cancer in patients who are currently receiving care at the HOPE clinic. Early detection of liver cancer may improve survival.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To estimate the sensitivity of the modified Center for Disease Control (CDC) hepatitis survey in diagnosing chronic hepatitis B virus (HBV) among HOPE clinic patient. SECONDARY OBJECTIVES: I. To estimate the sensitivity of the modified CDC hepatitis survey in identifying chronic active hepatitis C virus (HCV) infection among HOPE clinic patients. II. To estimate the sensitivity of fibrosis serum biomarkers, non-alcoholic fatty liver disease fibrosis score (NFS), fibrosis-4 index (FIB-4), and fatty liver index (FLI) in detecting fibrosis (fibroscan result >= F2) among HOPE clinic patients with metabolic conditions. III. To estimate the sensitivity of the Alcohol Use Disorder Identification Test Alcohol Consumption (AUDIT-C) in identifying fibrosis (fibroscan result >= F2) among HOPE clinic patients. IV. To estimate the sensitivity of the AUDIT-10 survey in identifying fibrosis (Fibroscan result >= F2) among Hope Clinic patients who scored >= 4 for men or >= 3 for women on the AUDIT-C. V. To estimate the specificity and accuracy of each of these risk factor screening tools in HOPE clinic patients. VI. To estimate the prevalence of fibrosis and cirrhosis risk factors among HOPE clinic patients. EXPLORATORY OBJECTIVES: I. To explore factors associated with each fibrosis/cirrhosis risk factor. II. To investigate differential diagnostic accuracy of screening methods by fibrosis severity. III. To evaluate the diagnostic performance of each dichotomized biomarker (NFS, FIB-4, and FLI) separately and assess biomarker optimal cutpoints for identifying fibrosis in the study population. OUTLINE: Patients complete surveys over 10-15 minutes, and undergo blood testing, clinical evaluation, and fibroscan at baseline. After completion of study, patients are followed up at 3 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04785534
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Active, not recruiting
Phase N/A
Start date December 22, 2020
Completion date August 30, 2024

See also
  Status Clinical Trial Phase
Terminated NCT03137706 - Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer
Recruiting NCT04410302 - Patient-Derived Xenografts to Reduce Cancer Health Disparities
Active, not recruiting NCT04505553 - Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer Phase 2
Recruiting NCT03990623 - CT Perfusion Scans in Detecting Changes in Blood Flow to the Liver After Portal Vein Embolization N/A
Completed NCT02520141 - Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery Phase 2
Recruiting NCT04929015 - Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study) N/A
Active, not recruiting NCT04251715 - mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma Phase 2
Completed NCT03819088 - Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer N/A